Limitless Potential. Precision Design. Enduring Impact.

HARNESSING THE UNLIMITED, SELF-RENEWING POTENTIAL OF iPSCs TO DRAMATICALLY AND POSITIVELY TRANSFORM THE LIVES OF PATIENTS SUFFERING FROM LIFE-THREATENING CANCERS

ABOUT US

We develop transformative, allogeneic, iPSC-derived NK and T cell therapies to create products for the treatment of both hematological and solid tumor malignancies with significant unmet medical need.

OUR SCIENCE

Our engineered, iPSC-derived allogeneic cell therapy platform was designed to yield therapies that overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.

NEWS & EVENTS

2021/11

Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a
Read more
2021/11

Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the ASH Annual Meeting Research and development update to be held on Thursday, December 16, 8:00-9:30 AM
Read more

CAREERS

We are seeking new team members motivated to advance the course of cancer care.

© Century Therapeutics 2021 | Legal